Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

0Tip RSCInsights

Authors

Andrés Ferreri•Kate Cwynarski34 more•Gerald Illerhaus

Journal

The Lancet Haematology

Published

April 9, 2016

Supporters

Support the authors with ResearchCoin

Tip RSC

Topics

Oncology

Medicine

Internal Medicine

Regimen

Cyclophosphamide

Show all topics

DOI

10.1016/s2352-3026(16)00036-3

License

Unknown License